This new working group aims to increase the level of adoption and trust in the in silico medicine technologies by their primary users: clinicians and healthcare professionals.
More and more in silico medicine technologies are emerging, they can be game changers in the clinical practice as well as in health product design and development but they can also be highly disruptive. Therefore, today more than ever, we need to involve all parties at stake in this process.
The VPHi has conducted a survey, of which the results call for the pursuit of actions in terms of awareness building, consultation and involvement. This is why we want to invest more efforts to reach out and involve the clinical community and healthcare professionals. Our strategy is to federate a group of actors, among the in silico scientific community and medical practitioners, who share the same objectives and are potentially already active towards the clinical community in order to coordinate actions to that endeavors.
The mission of the WG will be to foster the use and acceptance of in silico technologies by clinicians and healthcare professionals both in clinical practice and health product development. In order to achieve this goal, the group will focus on:
Establish privileged relationships with clinicians, clinical centers and opinion leaders
Consult and evaluate needs and concerns
Involve in technology development and co-design
Get involved in regulatory path development for in silico technologies
The participation to this group is open to all VPHi members, but we specifically encourage clinicians and/or healthcare professionals to join and contribute to this important initiative. Don’t hesitate to get your clinical collaborators on board – even when they are not VPHi member themselves.
If you're interested to join, please contact us.